Introduction
The annual influenza epidemics cause significant morbidity and mortality, particularly in elderly or frail individuals. Worldwide, the number of severe influenza infections is about 5 million each year leading to 500 000 deaths. About 75% of these fatalities are caused by influenza A viruses; the other 25% is due to influenza B virus. The widely recommended influenza vaccination requires annual updating and is only partially effective in some target populations. Besides, the influenza pandemic of 2009 demonstrated our vulnerability to new and suddenly appearing influenza viruses for which pre-existing immunity is lacking. Globally, the 2009 pandemic influenza virus killed 300 000 people within only 18 months; its death toll peaked in younger persons [1] . Influenza A viruses circulating in swine or birds can enter the human population and, hence, are a constant threat. For some circulating avian influenza A viruses, the mortality in humans is notoriously high, that is, 60% for H5N1 and 30% for H7N9.
As for antiviral therapy, virus resistance is widespread for the M2 channel blockers amantadine and rimantadine, and can also develop with the neuraminidase inhibitors (NAIs) oseltamivir and, to a lesser degree, zanamivir [2] . These two NAIs were stockpiled by many countries in the context of pandemic preparedness. Two newer analogues, peramivir and laninamivir octanoate, were recently approved in some regions. In 2014, the NAIs became matter of heavy debate after a Cochrane meta-analysis of clinical reports [3] concluded that oseltamivir and zanamivir exert only a small effect in shortening influenza disease in adults. On the other hand, a similarly large meta-analysis of individual patient data [4] determined that oseltamivir does reduce the duration of influenza illness as well as the risk for complications or hospitalization. Likewise, a study involving >29 000 patients who were hospitalized during the 2009 pandemic, demonstrated that the mortality risk was significantly reduced upon early NAI treatment [5] . Hence, NAIs are advocated for patients who are at risk for complicated influenza infections [6 ] .
We here review the recent progress in antiviral drug development for influenza. The (pre)clinical pipeline contains diverse agents (Table 1) many of which target the viral polymerase complex. Other approaches not covered here are: inhibitors of the viral NS1 protein [7] or host factors involved in virus replication [8] , such as the receptor destroying sialidase DAS-181 that is in Phase 2 clinical trials [9] .
Next-generation neuraminidase inhibitors and M2 channel blockers
Whereas the four NAIs mentioned above are reversible transition state mimetics of the NA reaction, a new class of 2,3-difluoro sialic acid derivatives was designed to bind to NA in a covalent manner. These analogues displayed favorable activity in influenza virus-infected cell culture and mouse models [10] . The lead compound proved active against the oseltamivir-resistant H275Y mutant form of N1 neuraminidase, and was less affected than zanamivir by the E119G neuraminidase mutation.
To address the issue of M2 blocker resistance, several groups [11] are applying crystallographic and NMR structural insights as well as molecular dynamics simulations to rationally develop new M2 inhibitors with activity against wild-type M2, or the clinically relevant S31N or V27A
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Targeting conserved sites in the viral hemagglutinin
The 18 hemagglutinin (HA) subtypes of influenza A are classified into two phylogenetic groups; the H1, H2 and H5 HAs belong to group 1 whereas the H3 and H7 HAs are in group 2. Also for influenza B, the circulating strains are classified into two lineages (B/Victoria and B/Yamagata). Despite high sequence diversity, some HA regions are conserved within the same group or across both groups of influenza A or B viruses. During recent years, several broadly neutralizing antibodies (bnAbs) (reviewed in [13, 14 ] ) with activity against group 1, group 2, or both influenza A HA groups, were isolated from plasma samples of influenza-infected or influenza-vaccinated individuals. This created the prospect for monoclonal antibody-based therapy. One bnAb (CR9114) recognizes an HA epitope conserved in influenza A and B viruses [15] . The known bnAb binding sites, revealed by cocrystallization, are located at, firstly, an HA globular head region, in most cases the receptor-binding site; secondly, an HA stem domain with a key role in membrane fusion; or thirdly, a membrane-proximal region at the base of the HA stem [13, 14 ] . Many bnAbs conferred protection in influenzainfected mouse models, presumably by engaging immune cells via Fc-FcgR interactions [16] . In vitro, the propensity to select escape mutants is much higher for anti-globular head than anti-stem bnAbs [13] . This does not exclude, however, that some bnAb binding stem epitopes may be prone to antigenic drift [17] . Several influenza bnAbs (CR8020, CR6261, MEDI8852, CT-P27, MHAB5553A, MHAA4549A and VIS410) are currently undergoing clinical evaluation; for the latter two some limited clinical data were recently disclosed [18, 19] .
A different agent interfering with the HA-mediated entry process is Flufirvitide-3 (FF-3), a 16-mer HA peptide sequence that entered Phase 1 trials [20] . The design of small-molecule inhibitors towards conserved regions in HA (such as the bnAb binding sites), seems particularly difficult. Various fusion inhibitors were reported to prevent HA refolding at low endosomal pH [21] , but their strict subtype-specificity and low resistance barrier have been serious drawbacks for preclinical development. For one H3-specific fusion inhibitor, the binding pocket in the HA stem [22] lies adjacent to the binding site for bnAb CR6261, emphasizing the key role of this region in the processes of HA refolding and fusion.
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Favipiravir (T-705)
This broad RNA virus inhibitor [31] was first reported in 2002. It was approved for influenza therapy in Japan in 2014, and is in Phase 3 trials in the USA and Europe. In one Phase 2 study [19] , favipiravir significantly reduced the time to resolution of symptoms without evidence of drug resistance in more than 700 samples tested. Mechanistically, favipiravir acts as a competitive substrate inhibitor of the viral polymerase after its conversion to favipiravir-ribosyl-5 0 -triphosphate (T-705-RTP) [32] . The low efficiency of its activation [33] appears one reason why favipiravir possesses relatively low antiviral potency. In enzymatic influenza polymerase assays, T-705-RTP mimics both GTP and ATP [34] , indicating that it acts as an ambiguous purine nucleotide due to its rotating carboxamide. Although the unmodified ribose allows RNA chain elongation, two consecutive T-705-RTP incorporation events result in 'leaky' chain termination [35] . In cell culture, favipiravir appears to inhibit viral RNA synthesis at high concentrations and produce viral mutagenesis at lower concentrations [36] . Besides having broad activity against influenza A and B, this drug has the advantage of an exceptionally high barrier for drug resistance. Until now, only one mutation (V43I in PB1; obtained in virus-infected cell cultures under ribavirin selection) was found to confer marginal (two-fold) resistance to favipiravir [37] ; the relevance of this substitution still needs to be verified in enzymatic polymerase assays.
Inhibitors of cap-binding by PB2
The azaindole compound VX-787 (new code: JNJ-872) is undergoing Phase 2b clinical evaluation after passing successful evaluation in an influenza challenge study in humans [19] . This promising agent displays nanomolar activity in influenza A virus-infected cell cultures and acts by interfering with cap-binding to PB2 [38 ] .
The crystal structure of the cap-binding domain (CBD) of PB2 in complex with 7-methyl-GTP was first revealed in 2008 [39] . Its recognition mechanism for capped RNA, in which the methylated guanine interacts with two aromatic residues in a cation-p sandwich, resembles that of other cap-binding proteins such as the eukaryotic initiation factor eIF4E. However, since the PB2-CBD has a distinct protein fold with a unique cluster of Phe residues ( Figure 1 , inset A), highly selective inhibitors are attainable. This is exemplified by VX-787, the product of structure-aided drug design in which an azaindole scaffold initially explored for inhibition of cellular kinases, was rationally optimized towards the influenza PB2-CBD. Its binding mode was clarified by cocrystallization ( Figure 1 , inset A) and confirmed by resistance selection in cell culture [40] . Development of PB2-CBD inhibitors with equal activity against influenza A and B seems challenging. Some residues (such as Phe-323) with a crucial role in binding VX-787 in the influenza A PB2-CBD, are not conserved in influenza B [41 ] . Also, the PB2-CBD of influenza B is more flexible, explaining its ability to recognize both methylated and unmethylated cap structures, as demonstrated by cocrystallization [41 ,42] and biochemical experiments [43] .
Inhibitors of the PA endonuclease
In early 2016, two PA inhibitors entered Phase 1 (AL-794) or Phase 2 (S-033188) clinical trials. The N-terminal part of PA (PA N ) carries the catalytic domain for cleavage of the capped host RNAs. Its core region contains one or two divalent metal ions (Mn 2+ or Mg 2+ ) and several residues that are conserved among influenza A and B viruses, given their role in catalysis or metal ion coordination (Figure 1 , inset B) [44, 45] . This catalytic center is surrounded by distinct hydrophobic pockets that are well suited for drug design [46, 47] . Hence, PA inhibitor design is currently built on chemical scaffolds bearing coplanar oxygens with the right geometry to coordinate the divalent metal ion(s), and to which hydrophobic elements have been added. The b-diketo acid derivative L-742,001 [48] serves as a prototype since it is the only reported inhibitor for which target and PA N binding mode have been confirmed in cell culture-based virus resistance studies [49] [50] [51] . Screening efforts with isolated PA N enzyme have yielded diverse PA inhibitors (see [46, 47] for examples). Quite a few of these hit compounds display only weak activity in virusinfected cell cultures, which is likely related to low cell penetration and/or insufficient antiviral selectivity. Crystallographic fragment screening plus hit optimization [52] delivered a hydroxypyridinone-based lead compound with remarkable potency (i.e. IC 50 value of 11 nM in a PA N enzyme assay), suggesting that its metal chelating motif and binding pose within PA N (Figure 1, inset B) are particularly relevant.
Inhibitors of the PB1 polymerase
The recent revelation of the active site structure of PB1 within the PA-PB1-PB2 heterotrimer [26 ,27 ] enables to rationally design inhibitors against this RNA-dependent RNA polymerase. Two possible lead compounds, identified by serendipitous screening, are compounds '367 0 [53] and 'ASN2 0 [54] which both select for a resistance mutation located at the outside of PB1, i.e. H456P for '367 0 and S499T for 'ASN2 0 . The conception of PB1 inhibitors towards the catalytic center for RNA elongation would be facilitated by a crystal structure of PB1 (or the polymerase heterotrimer) in complex with a natural NTP or structural analogue such as T-705-RTP.
Protein-protein interaction (PPI) inhibitors
In the crystal structure of PA C (the C-terminal domain of PA) in complex with the PB1 N-terminus (PB1 N ; residues 1-25), the binding pocket in PA C resembles a 'dragon's head' that clamps the PB1 N peptide into its 'jaws' [55, 56] .
The small size and hydrophobic nature of this pocket provided the foundation to design small-molecule PA C -PB1 N assembly inhibitors, the first of which were reported in 2012 [57] . These prevent the PA C -PB1 N interaction in biochemical assays and inhibit cell culture growth of influenza A (and, in some cases, also influenza B) virus (see [58 ] and references therein). Compound 'ANA-1' was shown to be effective in an influenza mouse model [59] . Cocrystallization or resistance studies with these PPI inhibitors are required to understand their precise binding mode within PA C .
Nucleoprotein-binding agents
The viral nucleoprotein (NP) is an attractive drug target since it is well conserved and has multiple regulatory and structural functions. To cover the viral RNA, it forms NP oligomers in which the tail loop inserts into the body domain of another NP molecule, and the RNA is bound in a groove lined by basic residues. Diverse small-molecule NP inhibitors with activity in virus-infected cell cultures have been discovered (see [60] and references therein). For the NP-aggregating agent nucleozin, the binding site in NP was identified by cocrystallization ( Figure 2 ) and viral resistance studies [61] . Nucleozin displayed nice efficacy in influenza mouse models, yet is inactive against some influenza strains with pre-existing resistance. This issue could be solved by targeting the highly conserved RNA binding groove, such as seen with the known pharmacological agents curcumin [62 ] and naproxen [63] .
Conclusion
During the past five years, enormous progress has been made in revealing the structure of several conserved influenza protein domains, creating ample opportunities for inhibitor design. We here briefly reviewed some concepts targeting the viral hemagglutinin, polymerase complex or nucleoprotein, for which antiviral leads are in the (pre)clinical stage. It can be anticipated that new influenza blockers will achieve market approval within the forthcoming years. Given the high sequence variation and mutability of influenza A and B viruses, we need an arsenal of drugs with different action mechanisms and resistance profiles, to address severe influenza infections in a population that is ageing and highly susceptible to new influenza viruses with pandemic potential.
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